Targets of Acinetobacter baumannii
Inventors
Urwyler, Simon • Haake, Markus • Rudolf, Michael
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10682404-B2
Publication Date
2020-06-16
Expiration Date
Abstract
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
Core Innovation
The invention relates to an immunogenic composition for generating an immune response against Acinetobacter baumannii. The composition comprises an isolated polypeptide encoded by a recombinant nucleic acid molecule having the polynucleotide sequence of SEQ ID NO: 13, together with an immuno-effective amount of an adjuvant.
In another aspect, the invention provides an immunogenic composition comprising an isolated recombinant antigenic polypeptide consisting of the amino acid sequence of SEQ ID NO: 14. The SEQ ID NO: 14 polypeptide is stated to have immunostimulatory activity and is formulated with an immuno-effective amount of an adjuvant. Additional antigenic polypeptides are specified by SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 16, while the composition can be constrained to exclude any additional Acinetobacter baumannii polypeptides beyond those specified.
The antigenic targets are described as Acinetobacter baumannii antigenic polypeptide targets including fragments, analogs, and derivatives, and include a monoclonal binding epitope consensus motif PVDFTVAI (SEQ ID NO:36). The document states that the identified targets are immunogenic in human and rabbits, are conserved across clinical isolates, and are expressed during infection.
The document further describes a selection approach for the targets based on shedome analysis, comparative proteomics, and convalescent patient sera immunoblot recognition. It also includes antibody and antigen-binding fragments specifically binding the defined antigens, with emphasis on the epitope consensus motif PVDFTVAI (SEQ ID NO:36).
Claims Coverage
The provided material includes two independent claims. Both independent claims focus on immunogenic compositions comprising specific isolated recombinant antigenic polypeptides or polypeptides defined by SEQ ID numbers, combined with an immuno-effective amount of an adjuvant.
Immunogenic composition with SEQ ID NO: 13 polypeptide and adjuvant
An immunogenic composition comprising an isolated polypeptide encoded by a recombinant nucleic acid molecule consisting of the polynucleotide sequence of SEQ ID NO: 13, and an immuno-effective amount of an adjuvant, effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Immunogenic composition with SEQ ID NO: 14 antigenic polypeptide and adjuvant
An immunogenic composition comprising an isolated recombinant antigenic polypeptide consisting of the amino acid sequence SEQ ID NO: 14 having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant.
Across the independent claims, the core claim coverage is compositions that generate an immune response against Acinetobacter baumannii using isolated recombinant antigenic polypeptides defined by SEQ ID NO: 13 or SEQ ID NO: 14, together with an immuno-effective amount of an adjuvant. Dependent claims add constraints such as inclusion of additional specified SEQ ID polypeptides and exclusion of any additional Acinetobacter baumannii polypeptides.
Stated Advantages
Generates an immune response against Acinetobacter baumannii in a subject in need thereof.
SEQ ID NO: 14 polypeptide has immunostimulatory activity.
The identified targets are immunogenic in human and rabbits, are conserved across clinical isolates, and are expressed during infection.
Documented Applications
An immunogenic composition effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.
Passive or active immunization formats.
Interested in licensing this patent?